Differentiation syndrome in acute promyelocytic leukaemia

93Citations
Citations of this article
151Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Acute promyelocytic leukaemia differentiation syndrome (APL DS) is seen when patients with APL are treated with all-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO). Presenting symptoms are varied but frequently include dyspnoea, unexplained fever, weight gain >5 kg, unexplained hypotension, acute renal failure and a chest radiograph demonstrating pulmonary infiltrates or pleural or pericardial effusion. Immediate treatment with steroids at the first clinical suspicion is recommended and ATRA/ATO should be stopped in severe cases or if there is no response to treatment. The utility of steroid prophylaxis in order to prevent APL DS is less certain. Here we provide a detailed review of the pathogenesis, clinical signs and symptoms as well as management and prophylaxis strategies of APL DS.

Cite

CITATION STYLE

APA

Stahl, M., & Tallman, M. S. (2019, October 1). Differentiation syndrome in acute promyelocytic leukaemia. British Journal of Haematology. Blackwell Publishing Ltd. https://doi.org/10.1111/bjh.16151

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free